Tesamorelin GHRH Protocol
Stabilized Growth Hormone-Releasing Hormone (GHRH) analogue studied for visceral fat reduction, lean mass preservation, and metabolic rate support.
infoResearch & Clinical Context
Targeted visceral fat reduction and body composition optimization protocol.
Mechanism & Biological Overview
Tesamorelin is a synthetic 44-amino acid analogue of Growth Hormone-Releasing Hormone (GHRH). It selectively binds to pituitary somatotroph receptors, stimulating natural, pulsatile growth hormone secretion to target stubborn visceral adipose tissue while preserving lean muscle mass.
Key Biological Highlights & Benefits
- checkTargeted reduction of deep abdominal (visceral) adipose tissue
- checkPreserves lean muscle mass and structural metabolic rate
- checkStimulates natural, physiological pulsatile Growth Hormone release
- checkSupports healthy triglyceride levels and lipid profiles
Scientific Literature Abstract
"Tesamorelin stimulates pituitary synthesis and release of endogenous growth hormone. Elevated GH acts directly on adipocytes via GH receptors, enhancing lipolysis through cyclic AMP activation, specifically targeting visceral fat depots."
hubTarget Receptor Pathways
Frequently Asked Questions
How does Tesamorelin specifically target visceral fat?
Visceral fat cells express higher density growth hormone receptors. Tesamorelin's GH-releasing effect selectively mobilizes lipolysis in deep abdominal fat.
Does Tesamorelin shut down natural growth hormone production?
No. Unlike exogenous growth hormone, Tesamorelin acts on the pituitary gland to preserve natural negative feedback loops and physiological GH pulsation.
Explore Related Scientific Interventions
Semaglutide Protocol
A GLP-1 receptor agonist studied for appetite modulation and glycemic signaling pathways in metabolic health.
Tirzepatide Dual Agonist
Dual GIP and GLP-1 receptor agonist targeting complementary metabolic pathways for body composition and appetite research.
Retatrutide Triple Agonist
Triple receptor agonist (GIP, GLP-1, and Glucagon) studied for its potential effects on metabolic rate and lipid mobilization pathways.
Clinical & Legal Disclaimer
Medical Disclaimer: Information provided on this website is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Product availability, indications, regulatory status, and suitability may vary. Any medical treatment should be considered with an appropriately qualified healthcare professional.
NOVAMET does not guarantee specific weight-loss, metabolic, or treatment outcomes.